Q1 Earnings Estimate for BDTX Issued By HC Wainwright

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Black Diamond Therapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.26) EPS and FY2027 earnings at ($0.96) EPS.

BDTX has been the topic of a number of other reports. BTIG Research boosted their price target on shares of Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings downgraded shares of Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, July 13th. Jefferies Financial Group reissued a “buy” rating on shares of Black Diamond Therapeutics in a research note on Thursday. Wall Street Zen cut Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, TD Cowen restated a “buy” rating on shares of Black Diamond Therapeutics in a research report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.83.

Black Diamond Therapeutics Stock Up 7.3%

Shares of NASDAQ BDTX opened at $1.92 on Friday. The firm has a 50-day simple moving average of $1.84 and a 200-day simple moving average of $2.27. The stock has a market capitalization of $110.02 million, a price-to-earnings ratio of -2.56 and a beta of 3.28. Black Diamond Therapeutics has a 52 week low of $1.60 and a 52 week high of $4.94.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BDTX. Cerity Partners LLC purchased a new stake in shares of Black Diamond Therapeutics in the second quarter valued at about $26,000. Hudson Bay Capital Management LP acquired a new position in Black Diamond Therapeutics in the 2nd quarter valued at about $26,000. nVerses Capital LLC acquired a new position in Black Diamond Therapeutics in the 4th quarter valued at about $26,000. Stokes Family Office LLC acquired a new position in Black Diamond Therapeutics in the 4th quarter valued at about $27,000. Finally, Brookstone Capital Management purchased a new stake in shares of Black Diamond Therapeutics in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.